Literature DB >> 11892836

Recombinant adeno-associated virus vector-transduced vascular endothelial cells express the thrombomodulin transgene under the regulation of enhanced plasminogen activator inhibitor-1 promoter.

J Mimuro1, S Muramatsu, Y Hakamada, K Mori, J Kikuchi, M Urabe, S Madoiwa, K Ozawa, Y Sakata.   

Abstract

We were able to facilitate plasminogen activator inhibitor 1 (PAI-1) promoter activity approximately by 14-fold using an enhancer element. This enhanced PAI-1 promoter has a strong basal activity, comparable to CAG promoter activity, and has a response similar to the PAI-1 promoter with respect to TGFbeta 1 and TNFalpha stimulation. The characteristics of the enhanced PAI-1 promoter are thought to be suited to timely and tissue-specific expression of anticoagulant molecules in the vascular cells. Thus, we developed recombinant adeno-associated virus (rAAV) vectors using the enhanced PAI-1 promoter and were successful in transducing vascular endothelial cells to express the thrombomodulin transgene under the regulation of the enhanced PAI-1 promoter in vitro. Thromobomodulin transgene expression driven by the enhanced PAI-1 promoter in rAAV vector-transduced cultured endothelial cells was between 600- and 1000-fold higher than constitutive thrombomodulin gene expression in cultured human umbilical vein endothelial cells and was up-regulated by TGFbeta1 and TNFalpha stimulation which may down-regulate endogenous thrombomodulin gene expression in endothelial cells. The brain vascular endothelial cells of Mongolian gerbils could also be transduced by the same rAAV vector in vivo. Transduction of endothelial cells by rAAV vectors to express enhanced PAI-1 promoter-driven transgenes may be a useful gene therapy approach for vascular diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11892836     DOI: 10.1038/sj.gt.3301579

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  5 in total

Review 1.  Targeting gene therapy vectors to the vascular endothelium.

Authors:  Lorraine M Work; Stuart A Nicklin; Andrew H Baker
Journal:  Curr Atheroscler Rep       Date:  2003-05       Impact factor: 5.113

2.  Safety of intra-articular transplantation of lentivirally transduced mesenchymal stromal cells for haemophilic arthropathy in a non-human primate.

Authors:  Tsukasa Ohmori; Hiroaki Mizukami; Yuko Katakai; Sho Kawai; Hitoyasu Nakamura; Makoto Inoue; Tsugumine Shu; Hideharu Sugimoto; Yoichi Sakata
Journal:  Int J Hematol       Date:  2018-05-08       Impact factor: 2.490

Review 3.  New vectors and strategies for cardiovascular gene therapy.

Authors:  Agnieszka Jazwa; Alicja Jozkowicz; Jozef Dulak
Journal:  Curr Gene Ther       Date:  2007-02       Impact factor: 4.391

4.  Short regulatory DNA sequences to target brain endothelial cells for gene therapy.

Authors:  Hanna Graßhoff; Helge Müller-Fielitz; Godwin K Dogbevia; Jakob Körbelin; Jacqueline Bannach; Carl Mg Vahldieck; Kristina Kusche-Vihrog; Olaf Jöhren; Oliver J Müller; Ruben Nogueiras; Vincent Prevot; Markus Schwaninger
Journal:  J Cereb Blood Flow Metab       Date:  2021-08-24       Impact factor: 6.960

Review 5.  Animal models for target diseases in gene therapy--using DNA and siRNA delivery strategies.

Authors:  Ian S Blagbrough; Chiara Zara
Journal:  Pharm Res       Date:  2008-10-08       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.